Preservation of Pancreatic β-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women

TABLE 5

Changes between baseline and 3 months in troglitazone responders according to magnitude of decrease in IVGTT insulin area during first 3 months

Small decrease* Large decrease P
n 42 31
Fasting glucose (mg/dl) −3.0 (−15.0, 10.0) −7.0 (−26.0, 1.0) 0.007
Kg (min−1/100) −0.02 (−0.66, 1.75) 0.17 (−1.69, 1.19) 0.30
SI (min−1 per μU/ml × 10−4) 1.49 (0.54, 7.69) 1.34 (0.54, 4.40) 0.63
Total insulin area (μU/ml × min) −1591 (−3053, 985) −6011 (−19364, −3160) <0.000
AIRg (μU/ml × min) −3 (−424, 364) −126 (−926, 255) 0.06
DI 428 (−727, 2416) 689 (−1822, 2732) 0.08
Pill compliance (% of prescribed)§ 93 (46, 99) 90 (62, 98) 0.54
  • Data are median (minimum, maximum).

  • *

    * Responders with change in IVGTT insulin area in tertiles 1 and 2, Table 3;

  • Responders with change in IVGTT insulin area in tertile 3, Table 3;

  • P < 0.01 for change from baseline within a group by Wilcoxon’s signed-rank test;

  • §

    § during first 3 months on trial.

This Article

  1. Diabetes vol. 51 no. 9 2796-2803